Psychopharmacological properties of calcium channel inhibitors
- 1 October 1992
- journal article
- review article
- Published by Springer Nature in Psychopharmacology
- Vol. 109 (1-2) , 12-29
- https://doi.org/10.1007/bf02245476
Abstract
The previous decade has witnessed a major expansion of knowledge of the role played by voltage-sensitive calcium channels in the function of the central nervous system. Significant progress in the field has been made possible with the broadening use of organic calcium channel inhibitors (CCIs, Ca2+ antagonists), until recently considered almost exclusively as peripherally active antianginal and antiarrhythmic drugs. CCIs, however, do penetrate the blood-brain barrier from the periphery. Autoradiographic studies have established a highly heterogeneous distribution of CCI recognition sites within the brain. The existing evidence suggests that CCIs have marked psychotropic properties. The profile of their central activity is unique and spans a wide range of effects. Nevertheless, question regarding potentially confounding potent peripheral effects of these drugs remain. This paper reviews the psychopharmacology of CCIs, concentrating on preclinical data, but including supportive clinical and biochemical evidence as well. It focuses on these drugs' antidepressant, antidopaminergic (neuroleptic-like), anxiolytic and anticonvulsant effects. CCIs may also modify the reinforcing properties of some addictive drugs.Keywords
This publication has 149 references indexed in Scilit:
- Do Calcium Antagonists Have a Place in the Treatment of Mood Disorders?Drugs, 1991
- Some central pharmacological effects of the calcium channel antagonist flunarizineJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1991
- Interactions between analgesics and calcium channel blockersGeneral Pharmacology: The Vascular System, 1990
- Antidopaminergic action of verapamil and several other drugs: Inactivation of vesicular dopamineLife Sciences, 1990
- Biochemical and behavioral evidence for an interaction between ethanol and calcium channel antagonistsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1988
- Calcium channel antagonists decrease the ethanol withdrawal syndromeLife Sciences, 1986
- In vivo effects of the Ca2+-antagonist nimodipine on dopamine metabolism in mouse brainJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1986
- Calcium-Antagonist DrugsNew England Journal of Medicine, 1985
- Calcium antagonist binding sites in the rat brain: Quantitative autoradiographic mapping using the 1,4-dihydropyridines [3H]PN 200-110 and [3H]PY 108-068Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1984
- The interaction of [3H]PY 108-068 and of [3H]PN 200-110 with calcium channel binding sites in rat brainJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1984